Engflag

Nitazoxanida

Quick links to important sections

Nitazoxanida

Nitazoxanida_ES

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nitazoxanida

Quick Facts

Property Description
Active ingredient Nitazoxanide
Form Tablet, Oral suspension
Pharmacological class Antiprotozoal, Anthelmintic
General purpose Elimination of parasitic organisms
Origin Synthetic compound (Acetamide derivative)

What is Nitazoxanide?

Nitazoxanide is a synthetic broad-spectrum antiparasitic agent used as a prescription-only medicine to help the body clear infections caused by various parasitic organisms. It is the prototype member of a chemically distinct group known as the Thiazolide class of drugs, clinically recognized for its efficacy against a wide variety of parasitic pathogens.

Nitazoxanide: Definition and Pharmacological Class

Nitazoxanide is a prescription-only synthetic compound belonging to the Thiazolide chemical class, which is defined as an Acetamide derivative. Its high-level classification is that of a broad-spectrum antiprotozoal and anthelmintic agent, confirming its effectiveness against both microscopic single-celled protozoa and parasitic worms. Nitazoxanide is indicated for specific parasitic infections and is categorized as an Antiprotozoal.

Origin, Composition, and General Purpose

The medication is a single active ingredient product, with therapeutic effects deriving solely from the compound Nitazoxanide. It is manufactured in standard oral dosage forms, which include a film-coated tablet and a powder for oral suspension. The general purpose of Nitazoxanide is achieved by selectively interfering with the energy metabolism required for the parasite's survival. The drug’s antiparasitic mechanism involves the inhibition of the Pyruvate Ferredoxin Oxidoreductase (PFOR) enzyme. This mechanism highlights the drug's specialized role in disrupting the parasite's vital internal processes.

How Nitazoxanide Differs from Other Antiparasitic Agents

Nitazoxanide's unique mechanism, which involves the inhibition of the PFOR enzyme, provides a distinct therapeutic strategy compared to older, chemically unrelated drug classes, such as nitroimidazoles or benzimidazoles. This specific target ensures the drug offers a specialized and crucial approach for parasitic infections by disrupting the core vitality of the organism, establishing its role as an important newer option in antiparasitic therapy.

Regulatory References

  1. NIH, PMC1803158

What side effects are possible with Nitazoxanida?

Possible side effects and safety information

The official regulatory documentation for Nitazoxanide describes a safety profile based on clinical data, classified by frequency and the physiological system affected. This information strictly details the documented possibilities without crossing into clinical advice.

Officially Documented Adverse Reactions

Adverse reactions are frequently observed within the Gastrointestinal Disorders and Nervous System Disorders organ classes. Reactions classified as common in regulatory documents—meaning they are most frequently reported—include nausea, abdominal pain, and headache. Other effects, such as discolored urine (often described as green or yellow) are also documented as common.

Serious adverse reactions that have been reported include hypersensitivity reactions (severe allergic responses).

Safety Considerations and Restrictions

Nitazoxanide is formally contraindicated in individuals with a known prior hypersensitivity to the active ingredient or any component of the formulation. This constraint establishes a clear regulatory boundary for use.

Caution is advised when the medicine is used in patients with underlying hepatic impairment (liver dysfunction) or renal impairment (kidney dysfunction). This requirement is based on the drug's known metabolic and elimination pathways. Furthermore, the drug's active metabolite is highly protein-bound, which requires consideration when co-administered with other highly protein-bound drugs, as noted in the official safety documents.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Nitazoxanida

Overdose Scope

  • Documented overdose presentations: Official regulatory documentation notes that information on Nitazoxanide overdosage is limited. Single oral doses up to 4000 mg have been administered to healthy adult volunteers without significant adverse effects.
  • Physiological systems affected (as stated in label): No specific severe adverse effects on physiological systems are documented in the human volunteer studies noted in the official regulatory OVERDOSAGE section.
  • Dose-related or exposure-related factors (if applicable): The highest recorded single dose in healthy adults without significant adverse effects was 4000 mg.
  • Population-specific overdose notes (if applicable): No specific population-based considerations (e.g., pediatric, hepatic impairment) are explicitly documented within the official OVERDOSAGE section.
  • Emergency-response statements (as written in official documents): Patients should be observed and must be given symptomatic and supportive treatment.
  • When immediate medical help is required (label-derived phrasing only): The official label requires that medical personnel observe the patient and implement the regulatory-mandated supportive care measures.

Overdose Classifications (High-Level)

  • Severity classification (as defined in official documents): Not formally classified; the data suggest a low acute toxicity profile at high single doses.
  • Regulatory basis (EMA / FDA / etc.): U.S. Food and Drug Administration (FDA) Prescribing Information.
  • Overdose-context constraints (as defined in official documents): The active metabolite, tizoxanide, is highly protein bound (greater than 99.9%), indicating that dialysis is unlikely to significantly reduce plasma concentrations.

Resulting Overdose Structure

Official overdose statements:

  • Regulatory information on overdosage is limited.
  • No specific antidote is known for this overdosage.
  • In the event of an overdose, patients must be observed and given symptomatic and supportive treatment.
  • Gastric lavage may be considered appropriate soon after oral administration.
  • Dialysis is unlikely to be effective due to the high protein binding of the active metabolite.

Connection to the overall overdose profile (2–4 sentences): The regulatory profile is characterized by limited clinical data, noting that high single doses have not resulted in significant adverse effects. Emergency management is strictly defined by the need for observation and the implementation of symptomatic and supportive care, given that no specific antidote is available to reverse the effects of an overdose.

Therapeutic Uses of Nitazoxanida

Nitazoxanide is utilized in the management of specific infections that lead to severe diarrhea. This medication is generally used in situations involving certain distressing symptoms that interfere with daily functioning.

Managing Acute Gastrointestinal Illness

Nitazoxanide is applied in clinical settings for conditions characterized by acute, disruptive symptom manifestations caused by specific protozoan (parasitic) infections, such as those involving Giardia lamblia or Cryptosporidium parvum. It is commonly used to help with pronounced gastrointestinal distress, including acute, persistent diarrhea, severe abdominal cramps, and associated systemic discomfort like fever. This specialized use provides a targeted therapeutic domain that assists with maintaining functional stability during the illness.

“The drug is considered relevant for episodes associated with significant discomfort and helps address symptom clusters that may become intense or disruptive.”

Patient Benefits and Symptom Support

By addressing the cause of the illness, the medication contributes to improved comfort during periods of heightened symptoms and may offer symptomatic relief that helps ease the physical burden of constant digestive upset. It also supports general well-being during symptomatic phases and aids patients during difficult episodes by easing distress.

Quick Fact: Relief for Diarrhea This drug is commonly used across conditions presenting with acute episodes where persistent diarrhea and severe abdominal discomfort are the main complaints.

Regulatory References

  1. NIH DailyMed Prescribing Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Nitazoxanide

Official regulatory documents define strict population eligibility for Nitazoxanide based on age, hypersensitivity, and underlying health conditions.

Contraindications and Restrictions

Classification Population Status Defined by Regulators
Absolute Contraindication Patients with prior hypersensitivity to nitazoxanide or excipients Must not use
Use Not Established Infants under 1 year of age Safety and efficacy not established
Limited Efficacy Immunodeficient/HIV patients (C. parvum diarrhea indication) Efficacy not shown

Age-Specific Eligibility

Nitazoxanide use is dependent on age and formulation. The oral suspension is approved for pediatric patients 1 year of age and older. The 500 mg tablets are approved for patients 12 years of age and older (adults and adolescents); the tablets must not be administered to patients 11 years or younger.

Conditional Use

Caution is required when administering Nitazoxanide to patients with compromised renal or hepatic function, as the drug's effects have not been fully studied in these populations. For nursing women, caution should be exercised as it is not known whether the drug is excreted in human milk.

What should I know about interactions with other medicines?

The interaction profile for Nitazoxanide is defined by specific pharmacokinetic constraints documented in regulatory labeling.

The active metabolite, Tizoxanide, is highly bound to plasma proteins, with binding exceeding 99.9%. This characteristic creates the potential for a pharmacokinetic interaction with other highly plasma protein-bound medicines that possess a narrow therapeutic index, such as the anticoagulant Warfarin. Official regulatory information advises monitoring the co-administered drug when combined, as competition for protein binding sites may lead to altered systemic exposure.

A key constraint relates to administration timing with food. Official documents state that taking Nitazoxanide with a meal significantly enhances the drug's oral bioavailability, leading to increased systemic concentration (AUC and C max) of Tizoxanide and its glucuronide conjugate.

Regarding metabolic pathways, the regulatory documentation states that no significant drug-drug interaction is expected when Nitazoxanide is co-administered with medicines that are metabolized by or that inhibit Cytochrome P450 (CYP) enzymes. Additionally, the pharmacokinetics of the drug in patients with impaired hepatic or renal function have not been formally studied, which is noted in the official labeling as a consideration.

Mechanism of Action

Blocking Pathogen Energy Metabolism

Nitazoxanide’s primary action is through its active metabolite, tizoxanide, which inhibits the pyruvate:ferredoxin/flavodoxin oxidoreductase ( PFOR) enzyme in anaerobic bacteria and protozoa. This blockade disrupts the parasite's vital anaerobic energy pathway, resulting in rapid ATP depletion, leading to inhibited proliferation and cell death of the organism.

️ Modulating Host Immunity and Inflammation

Beyond mechanisms targeting pathogens, the drug exerts a distinct influence on host defense systems. It acts as a modulator by inhibiting the production of key pro-inflammatory cytokines (like TNF-alpha) while simultaneously stimulating processes like autophagy (cellular cleanup) in host cells. This dual action modulates inflammatory cytokine release and stimulates host antiviral and cellular clearance mechanisms, leading to the modulation of inflammatory and cellular responses.

Multi-Target Action and Antiviral Pathways

The drug's spectrum is achieved by targeting multiple distinct molecular mechanisms. In addition to PFOR inhibition, the metabolite interferes with specific viral protein maturation and activates host factors (like eIF2alpha) that restrict viral protein synthesis. This multi-target cascade influences metabolic and inflammatory signaling processes, resulting in the physiological consequence of reduced pathogen burden and immune response modulation.

Dosage and Administration Information

The administration of Nitazoxanide consists of a fixed, short-term oral course twice daily. The route of administration for both the tablet and the oral suspension is oral. Dosing regimens, regardless of age group or formulation, involve taking the medicine with food to help systemic absorption. The duration of the course is three consecutive days for all indications and age groups.

Standard Dosing and Administration

For adults and adolescents 12 years of age and older, the standard dose is 500 mg per dose, taken every 12 hours.

Dosing for pediatric patients requires specific adherence to the formulation rules. For patients 11 years of age and younger, the 500 mg tablet is not utilized because a single tablet exceeds the recommended pediatric dose. These patients use the oral suspension, with doses ranging from 100 mg to 200 mg every 12 hours, depending on age group.

Age Group Dose (Every 12 Hours) Duration
Adults and 12 years and older 500 mg (Tablet or Suspension) 3 days
4 to 11 years 200 mg (Oral Suspension) 3 days
1 to 3 years 100 mg (Oral Suspension) 3 days

When using the oral suspension, the mixture is shaken well before each dose is measured with a calibrated device. Any reconstituted suspension that remains unused after a period of seven days is discarded. If a dose is missed, the standard procedure is to take it as soon as possible on the same day; otherwise, the missed dose is skipped to resume the regular schedule.

This protocol describes the parameters for the use of the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nitazoxanida

This section describes the research that has been conducted to study Nitazoxanida, focusing on the types of trials, the outcomes they measured, and areas where evidence is still limited or emerging. This information is a non-advisory summary of the existing research landscape.

Evidence for Diarrhea Caused by Giardia lamblia

The body of research for the use of Nitazoxanida in conditions associated with Giardia lamblia involves Randomized Controlled Trials (RCTs). These studies were designed to include active-controlled trials, where Nitazoxanida was evaluated alongside another antiparasitic medication. Research was applied in studies examining patient-reported experiences of physical discomfort related to acute diarrhea in immunocompetent children, adolescents, and adults.

Studies monitored two main outcomes: clinical response, which tracks how symptoms like diarrhea evolve, and parasitological response, which monitored the presence or absence of the parasite in stool samples. Findings describe patterns observed in these studies, documenting the short-term evolution of symptoms. Research describes the evaluation of the medicine in this setting, where regulatory reviews determined the clinical results were sufficient.

Evidence for Diarrhea Caused by Cryptosporidium parvum

The research base for Cryptosporidium parvum infection is centered on double-blind, placebo-controlled studies. The studies were structured to measure outcomes related to physical discomfort, specifically tracking outcomes related to clinical response (acute diarrhea changes) and parasitological response (the presence or absence of C. parvum oocysts in stool samples). Findings were compared to the placebo group, and trials described patterns related to both symptom changes and microbiological clearance in immunocompetent children and adults.

Research Gaps and Limitations

Clinical research generally focuses on short-term symptom changes, with follow-up typically limited to around 7 to 10 days. There is limited information for long-term outcomes or the durability of effect beyond these short assessment periods. Research has not fully established how symptoms may evolve over extended periods, and long-term effects, such as the likelihood of recurrence, are not well characterized.

Furthermore, evidence for use in immunodeficient patients—including those with HIV/AIDS—is insufficient, and data available for effectiveness in these specific subgroups are limited. For Cryptosporidium parvum, research observed patterns where the changes in reported symptoms did not always correlate consistently with the microbiological clearance of the parasite.

Frequently Asked Questions (FAQ)

Common questions about Nitazoxanida (FAQ)

Q: Does Nitazoxanida treat bacterial infections or only parasites?

The official indications for Nitazoxanide are for the treatment of diarrhea caused by the protozoa Giardia lamblia and Cryptosporidium parvum. Regulatory information notes the drug's mechanism of action involves interfering with energy pathways in anaerobic bacteria and protozoa. However, according to the official product information, the medicine is not FDA-approved for treating general bacterial infections.

Q: What types of parasites is Nitazoxanida usually prescribed for?

According to regulatory documents, Nitazoxanide is indicated for treating diarrhea caused by the parasites Giardia lamblia and Cryptosporidium parvum in patients whose immune systems are functioning normally. These are the specific parasitic infections for which the medication is officially approved.

Q: Do people take Nitazoxanida for any stomach issues that aren't parasitic?

The approved uses for Nitazoxanide are strictly limited to treating diarrhea that has been specifically linked to the parasites Giardia lamblia or Cryptosporidium parvum. The official labeling does not include indications for general or non-parasitic stomach issues.

Q: How often do people experience nausea or stomach upset with Nitazoxanida?

Clinical studies found that abdominal pain and nausea were among the most common adverse reactions reported by patients. Regulatory documents state these effects were observed in ge2% of the HIV-uninfected participants during the clinical trials. These are among the most frequently observed side effects.

Q: Does Nitazoxanida interact with common pain relievers like ibuprofen?

Official labeling advises caution when using Nitazoxanide alongside other medications that are highly bound to plasma proteins and have a narrow therapeutic window. The active metabolite of Nitazoxanide is highly protein-bound (over 99.9%), creating a potential for interaction where other highly protein-bound drugs might be affected. This caution applies generally to highly plasma protein-bound drugs and should be considered for any co-administered medicine.

Q: Are there certain foods or drinks I should avoid while on Nitazoxanida?

Official product information emphasizes that Nitazoxanide must be taken with food to help the body absorb the medicine properly. The manufacturer does not list specific foods or drinks that must be strictly avoided during the short course of treatment. Consulting a healthcare provider can offer personalized guidance on dietary choices.

Q: Can I take Nitazoxanida if I am currently taking medication for high blood pressure?

No specific interaction with anti-hypertensive medications is listed in official documents. However, due to the drug’s high plasma protein binding, caution is generally recommended for all highly protein-bound drugs. Official information recommends that patients review all co-administered prescription and nonprescription products with a healthcare provider.

Q: Is Nitazoxanida appropriate for use during pregnancy?

According to the official labeling, there is no available human data regarding the use of Nitazoxanide in pregnant women to inform a drug-associated risk. Studies conducted in animals did not show evidence of harm to the developing fetus. The decision to use the drug during pregnancy involves reviewing the known animal data against the mother's clinical need.

Q: Are there restrictions on using Nitazoxanida while breastfeeding?

Official information states that it is not known whether the medicine or its metabolites pass into human milk, nor are the effects on the breastfed infant established. The regulatory statement indicates the benefits of breastfeeding should be considered against the mother's clinical need and the lack of data on infant risk.

Q: How long does Nitazoxanida stay in your system after you stop taking it?

Nitazoxanide is rapidly metabolized into its active form, tizoxanide, shortly after being taken. Pharmacokinetic studies report that tizoxanide has a terminal half-life of approximately 1.3 to 1.8 hours in adults. This half-life describes the time required for the body to eliminate half the concentration of the active metabolite.

Q: Why do some people report bright yellow eyes or skin when taking this medicine?

Postmarketing experience has included reports of jaundice (yellowing of the skin and eyes) as a potential adverse effect. Discoloration of the eyes, often described as pale yellow, has also been noted. These reactions are considered rare, with the most common effect on color being discolored urine.

Q: Is it normal to feel a bit tired while on Nitazoxanida?

While not listed among the most common adverse effects, reports of fatigue (asthenia), malaise, and somnolence (drowsiness) have been noted in postmarketing experience. The reporting of these effects suggests an individual's response to the medication should be monitored.

Q: Can Nitazoxanida be used to treat 'traveler's diarrhea'?

Nitazoxanide is only formally approved for treating diarrhea specifically caused by the parasites Giardia lamblia or Cryptosporidium parvum. It is not indicated as a broad-spectrum treatment for all unspecified causes of 'traveler's diarrhea'.

Q: Are there common drug classes that interact with Nitazoxanida?

The primary interaction concern noted in regulatory documents involves other highly plasma protein-bound drugs that have a narrow therapeutic index. Because the active metabolite of Nitazoxanida is highly protein-bound, there is a potential for competition that could alter the systemic exposure of co-administered drugs.

Q: Does Nitazoxanida cause dizziness or affect driving?

Dizziness has been reported in postmarketing experience as a potential effect. Because this side effect has been noted, official product information advises that individuals assess their own response to the medication before engaging in activities that require full mental alertness, such as driving.

Q: Is Nitazoxanida generally well-tolerated?

In clinical trials, Nitazoxanide was observed to be generally well-tolerated. The most frequently reported adverse effects were mild in nature, including headache, abdominal pain, nausea, and changes in urine color (chromaturia).

Q: Is there a link between Nitazoxanida and changes in blood sugar?

Regulatory information notes that the oral suspension formulation of Nitazoxanide contains sucrose (sugar). Patients who have diabetes mellitus should be advised of this sugar content when the oral suspension formulation is being considered for use. The tablet formulation does not contain sucrose.

Q: How effective is Nitazoxanida according to published research?

Clinical trials conducted for the approved indications described that Nitazoxanide met specific clinical and parasitological response endpoints. These studies documented the clearance of the parasites Giardia lamblia and Cryptosporidium parvum in immunocompetent patients who completed the short course of treatment.

Q: What are the main risks associated with taking Nitazoxanida?

Official labeling identifies the main risks as the potential for severe hypersensitivity or allergic reactions, which is an absolute contraindication for use. Additionally, caution is advised for patients with underlying liver or kidney disease, as the drug's effects have not been fully studied in those populations.

Q: Do I need to avoid alcohol completely while taking Nitazoxanida?

Official regulatory documents do not list a specific formal restriction or warning regarding the complete avoidance of alcohol consumption while taking Nitazoxanide. Consulting a healthcare provider can offer personalized guidance regarding alcohol consumption during the treatment period.

How should Nitazoxanida be stored and disposed of?

Storage and Disposal Requirements for Nitazoxanide

The required conditions for storing Nitazoxanide are defined by regulatory labeling to maintain product stability, differentiating between the tablet and suspension forms.

Storage Requirements

Nitazoxanide tablets and the unsuspended powder for oral suspension must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F to 77 F). The tablets must be kept in the original container and be protected from moisture. All forms of the medicine must be stored out of the reach of children.

Stability and Handling

Once the oral suspension is reconstituted, it is stable for only 7 days. The container must be kept tightly closed during this period. Any portion of the suspension remaining after the 7-day stability period must be discarded.

Disposal Instructions

For the disposal of expired or unused medicine, individuals should consult a healthcare professional or pharmacist for instructions. Disposal must align with established local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Nitazoxanida found in:

A-Z Index: